drugset / Trial / NCT07247110
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | MK-4716 | Unknown | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |